


MJ33-OH lithium

Cat. No.:	HY-129944A
CAS No.:	1135306-36-3
Molecular Formula:	C ₂₂ H ₄₃ F ₃ LiO ₇ P
Molecular Weight:	514.48
Target:	Phospholipase
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



BIOLOGICAL ACTIVITY

Description	MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 ^[1] .
In Vivo	MJ33 (0.5 μM/kg; by tail vein, at 24 h before MCAO) significantly blocks the increase IL-1β, IL-17 and IL-23 in rats stimulated by Prdx6 siRNA treatment ^[2] . Compared with the Prdx6 siRNA group, combined exposure to Prdx6 siRNA and MJ33 significantly downregulates the mRNA and protein expression of NF-κB, iNOS and COX-2 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Shanshan Y, et al. Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury. *Front Cell Neurosci.* 2017 Apr 5;11:99.
- [2]. Moawad AR, et al. Deficiency of peroxiredoxin 6 or inhibition of its phospholipase A2 activity impair the in vitro sperm fertilizing competence in mice. *Sci Rep.* 2017 Oct 11;7(1):12994.
- [3]. Fisher AB, et al. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. *J Lipid Res.* 2005 Jun;46(6):1248-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA